Browse the corpus

©2013 UpToDate ® Print Email Results of selected series of cytoreduction and HIPEC for patients with MPM Center N Optimal cytoreduction* (percent) HIPEC agents Survival Prognostic factors Preoperative mortality/morbidity (percent) Median follow-up, months Median survival, months Overall (percent) Loggie B; 2001 (phase II trial). Wake Forest, NC. 12 5 (42) MMC 45 34 1 year: 60 NR 8/NR 3 years: 50 5 years: 33 7 years: 33 Deraco M; 2003 (phase II multi-institutional). Milan. 61 46 (74) Cisplatin + MMC or cisplatin + doxorubicin 20 NR 5 years: 54 Optimal resection 0/23 (grade 3) Feldman A; 2003 (phase II trial). NCI, Bethesda. 49 43 (88) Cisplatin (n = 49); with 5-FU/paclitaxel (n = 35) 28 92• 1 year: 86 Optimal resection, age <60, no deep invasion 0/36 3 years: 59 Brigand C; 2006 (retrospective). Centre Hospitale Lyon Sud. 15 11 (73) Cisplatin + MMC 47 36 1 year: 69 Optimal resection, extent of carcinomatosis 0/40 3 years: 43 5 years: 29 Deraco M; 2006 (phase II trial). Milan. 49 43 (88) Cisplatin + MMC or cisplatin + doxorubicin 20 NR 1 year: 88 Optimal resection, mitotic count 0/27 3 years: 65 5 years: 57 Yan T; 2007 (retrospective). Washington Hospital Center. 70 52 (74) Cisplatin + doxorubicin 35 59 1 year: 82 Optimal resection, female gender 3/41 (grade 3 to 4) 3 years: 57 5 years: 49 Hesdorffer M; 2008 (phase II trial). Columbia-Presbyterian, NY. 27 NR Cisplatin + MMCΔ 90 70 3 years: 67 Bulky disease, histology, pleural plaques 0/19 Chua T; 2009 (retrospective). Sydney, Australia. 20 19 (95) Cisplatin + doxorubicin 48 30 1 year: 78 Histology, subtype, optimal resection 5/20 (grade 3 to 4) 3 years: 46 Yan T; 2009 (multi-institutional series) 405 187 (46) Cisplatin + doxorubicin (n = 336); cisplatin, MMC, or both (n = 65) 33 53 1 year: 81 Histology, optimal resection, absence of lymph node metastases 2/31 (grade 3 to 4) 3 years: 60 5 years: 47 HIPEC: hyperthermic intraperitoneal chemotherapy; NR: not reported; MMC: Mitomycin C. * Optimal cytoreduction is defined as no residual tumor deposits >2.5 mm. • This series included patients (36 percent of all in the report) with low grade mesothelioma variants. Δ These investigators employ an aggressive multimodality approach with cytoreductive surgery followed by four months of intraperitoneal cisplatin, doxorubicin and interferon via indwelling catheter, followed by secondary cytoreductive surgery with IHPC (cisplatin plus MMC) and then whole abdominal radiotherapy.